GEN Exclusives

More »

GEN News Highlights

More »
Jul 16, 2014

Pfizer to Acquire InnoPharma for Up to $360M

  • Pfizer said today it will acquire InnoPharma for $225 million upfront, plus an additional up-to-$135 million tied to milestones, in a deal that expands the buyer’s generic and injectable drug offerings.

    InnoPharma’s current portfolio includes 10 generic products approved by the FDA, as well as a pipeline of 19 additional products under review by the agency, and more than 30 injectable and ophthalmic products under development.

    InnoPharma specializes in developing new formulations of existing drugs for cancer and central nervous disorders—including products that are deemed hard-to-make because they require complex manufacturing capabilities or have bio-equivalency challenges.

    Established in 2005, InnoPharma has an R&D facility in Piscataway, NJ, with capabilities in complex injectable delivery forms—including pens and depot injectables. The company has been working to leverage its expertise to expand into new dosage forms, including oral suspensions and nasal. InnoPharma’s portfolio already includes among its formulations solutions, suspensions, lyophilized, emulsions, liposomes, micelles, and lipid complexes.

    “Today’s announcement is an important milestone as we continue to look for innovative growth opportunities for our sterile injectables portfolio, which will increase to seventy three products with this acquisition,” John Young, group president, Pfizer Global Established Pharma (GEP), said in a statement.

    Pfizer Injectables is part of GEP, and includes the manufacturing, production and sale of human pharmaceutical and surgiceutical products. Pfizer will expand its active sterile injectable portfolio from the current 44 products to 73 products, include drugs that are currently marketed and drugs filed with the FDA.

    The deal is subject to regulatory approvals and is expected to be completed in the third quarter, Pfizer and InnoPharma said.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?